Treatment Guidelines
HIV Treatment Guidelines
DHHS Updates Perinatal Antiretroviral Treatment Guidelines
- Details
- Category: HIV Treatment Guidelines
- Published on Thursday, 15 September 2011 00:00
- Written by DHHS
The Department of Health and Human Services has once again updated its Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States.
Federal HIV Treatment Guidelines Panel Releases Information on Rilpivirine (Edurant)
- Details
- Category: HIV Treatment Guidelines
- Published on Wednesday, 17 August 2011 00:00
- Written by Liz Highleyman
The U.S. HIV treatment guidelines panel this week issued a supplement to its Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, providing information about the most recently approved antiretroviral drug, the NNRTI rilpivirine (brand name Edurant). Rilpivirine was approved this past May, and a combination pill (Complera) containing rilpivirine, tenofovir, and emtricitabine was approved last week. 
New HRSA Guide for HIV/AIDS Clinical Care
- Details
- Category: HIV Treatment Guidelines
- Published on Tuesday, 28 June 2011 06:37
- Written by HRSA
An updated version of the Health Resources and Services Administration (HRSA) Guide for HIV/AIDS Clinical Care is now available free online.
DHHS Issues Updated Pediatric Antiretroviral Treatment Guidelines
- Details
- Category: HIV Treatment Guidelines
- Published on Friday, 12 August 2011 00:00
- Written by Liz Highleyman
On August 11, 2011, the U.S. Department of Health and Human Services (DHHS) issued the latest revision of its Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.
Revised U.S. Antiretroviral Therapy Guidelines Call for Earlier Treatment and Promote Raltegravir (Isentress) to a Preferred First-line Option
- Details
- Category: HIV Treatment
- Published on Friday, 04 December 2009 13:13
- Written by Liz Highleyman
On December 1, the U.S. Department of Health and Human Services (DHHS) updated its guidelines for antiretroviral therapy (ART) for HIV positive adults and adolescents. In keeping with recent research, the revision calls for earlier treatment. ART is now recommended for people with 350-500 cells/mm3, and half the expert panel favored treatment even for those with more than 500 cells/mm3. For first-line therapy, the integrase inhibitor raltegravir (Isentress) was added to the list of "preferred" options, while lopinavir/ritonavir (Kaletra) was changed to an "alternative" due to side effects.
Web Design and Development by